Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sambuddha Chakraborty & Ashwini Chauhan. (2023) Fighting the flu: a brief review on anti-influenza agents. Biotechnology and Genetic Engineering Reviews 0:0, pages 1-52.
Read now
Read now
Cecilia Trucchi, Marco D’Amelio, Daniela Amicizia, Andrea Orsi, Idalba Loiacono, Roberta Tosatto, Maria Francesca Piazza, Chiara Paganino, Andrea Pitrelli, Giancarlo Icardi & Filippo Ansaldi. (2021) Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region. Human Vaccines & Immunotherapeutics 17:5, pages 1387-1395.
Read now
Read now
Antonino Bella, Francesco Gesualdo, Andrea Orsi, Claudia Arcuri, Maria Chironna, Daniela Loconsole, Christian Napoli, Giovanni Battista Orsi, Ilaria Manini, Emanuele Montomoli, Valeria Alfonsi, Maria Rita Castrucci & Caterina Rizzo. (2019) Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season. Expert Review of Vaccines 18:6, pages 671-679.
Read now
Read now
Alberto Pérez Rubio & Jose María Eiros. (2018) Cell culture-derived flu vaccine: Present and future. Human Vaccines & Immunotherapeutics 14:8, pages 1874-1882.
Read now
Read now
Articles from other publishers (34)
Francesco Bruno, Paolo Abondio, Rossella Bruno, Leognano Ceraudo, Ersilia Paparazzo, Luigi Citrigno, Donata Luiselli, Amalia C. Bruni, Giuseppe Passarino, Rosanna Colao, Raffaele Maletta & Alberto Montesanto. (2023) Alzheimer’s disease as a viral disease: Revisiting the infectious hypothesis. Ageing Research Reviews 91, pages 102068.
Crossref
Crossref
Chia-Ying Wu, Shao-En Kao, Yung-Chieh Tseng, Yu-Po Lin, Jen-Tzu Hou, Li-Yang Wu, Sharon Chiu, Che Alex Ma, Pei-Wen Hsiao, Jane Hsiao & Juine-Ruey Chen. (2023) Pilot-scale production of inactivated monoglycosylated split H1N1 influenza virus vaccine provides cross-strain protection against influenza viruses. Antiviral Research 216, pages 105640.
Crossref
Crossref
Alla Heider, Marianne Wedde, Ralf Dürrwald, Thorsten Wolff & Brunhilde Schweiger. (2022) Molecular characterization and evolution dynamics of influenza B viruses circulating in Germany from season 1996/1997 to 2019/2020. Virus Research 322, pages 198926.
Crossref
Crossref
Praveen M. Varghese, Uday Kishore & Reena Rajkumari. (2022) Innate and adaptive immune responses against Influenza A Virus: Immune evasion and vaccination strategies. Immunobiology 227:6, pages 152279.
Crossref
Crossref
Núria Soldevila, Luca Basile, Ana Martínez, Núria Torner, M. Ángeles Marcos, Maria del Mar Mosquera, Andrés Antón, Cristina Andrés, Cristina Rius, Tomàs Pumarola & Ángela Domínguez. (2022) Surveillance of influenza B severe hospitalized cases during 10 seasons in Catalonia: Does the lineage make a difference?. Journal of Medical Virology 94:9, pages 4417-4424.
Crossref
Crossref
Jaline Cabral da Costa, Marilda Mendonça Siqueira, David Brown, Jonathan Oliveira Lopes, Braulia Caetano da Costa, Eric Lopes Gama & Maria de Lourdes Aguiar-Oliveira. (2022) Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B Victoria and Yamagata Infections in Brazil over the Decade 2010–2020: A Statistical and Phylogeny–Trait Analyses. Viruses 14:7, pages 1477.
Crossref
Crossref
Noura M. Abo Shama, Sara H. Mahmoud, Ola Bagato, Elsayed Tarek AbdElsalam, Maha Alkhazindar, Ahmed Kandeil, Pamela P. McKenzie, Richard J. Webby, Mohamed A. Ali, Ghazi Kayali & Rabeh El-Shesheny. (2022) Incidence and neutralizing antibody seroprevalence of influenza B virus in Egypt: Results of a community-based cohort study. PLOS ONE 17:6, pages e0269321.
Crossref
Crossref
Ajitanuj Rattan, Chantelle L. White, Sean Nelson, Max Eismann, Herbey Padilla-Quirarte, Maryah A. Glover, Thamotharampillai Dileepan, Bindumadhav M. Marathe, Elena A. Govorkova, Richard J. Webby, Katherine A. Richards & Andrea J. Sant. (2022) Development of a Mouse Model to Explore CD4 T Cell Specificity, Phenotype, and Recruitment to the Lung after Influenza B Infection. Pathogens 11:2, pages 251.
Crossref
Crossref
Gaël Dos Santos, Hao Wang, Pooja Jindal, Maria Rybo, Hélène Roul, Sridevi Pallem, Tamara Eckermann, Lode Godderis, Xavier Martínez Gómez, Eric Godard, Muriel Soler, Mitra Yousefi, Ignacio Salamanca de la Cueva & Ugo Nwoji. (2021) Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season. Infectious Diseases and Therapy 11:1, pages 463-483.
Crossref
Crossref
Gabor Keresztes, Mark Baer, Mark R. Alfenito, Theo C. Verwoerd, Andriy Kovalchuk, Marilyn G. Wiebe, Tor Kristian Andersen, Markku Saloheimo, Ronen Tchelet, Richard Kensinger, Gunnveig Grødeland & Mark Emalfarb. (2022) The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines. Vaccines 10:2, pages 148.
Crossref
Crossref
Adam M. Sandor, Michael S. Sturdivant & Jenny P. Y. Ting. (2021) Influenza Virus and SARS-CoV-2 Vaccines. The Journal of Immunology 206:11, pages 2509-2520.
Crossref
Crossref
Manjusha Gaglani, Anupama Vasudevan, Chandni Raiyani, Kempapura Murthy, Wencong Chen, Michael Reis, Edward A Belongia, Huong Q McLean, Michael L Jackson, Lisa A Jackson, Richard K Zimmerman, Mary Patricia Nowalk, Arnold S Monto, Emily T Martin, Jessie R Chung, Sarah Spencer, Alicia M Fry & Brendan Flannery. (2021) Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011–2012 to 2016–2017. Clinical Infectious Diseases 72:7, pages 1147-1157.
Crossref
Crossref
Florian Colrat, Edward Thommes, Nathalie Largeron & Fabián P. Alvarez. (2021) Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. Vaccine 39, pages A42-A50.
Crossref
Crossref
Zachary R. Sia, Matthew S. Miller & Jonathan F. Lovell. (2020) Engineered Nanoparticle Applications for Recombinant Influenza Vaccines. Molecular Pharmaceutics 18:2, pages 576-592.
Crossref
Crossref
Chia-Yuan Chang, Ching-Yi Cho, Chou-Cheng Lai, Chun-Yi Lu, Luan-Yin Chang, Miao-Chiu Hung, Li-Min Huang & Keh-Gong Wu. (2020) Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study. Vaccine 38:22, pages 3839-3846.
Crossref
Crossref
Chenyang Huang, Xiaofang Fu, Yuqing Zhou, Fenfang Mi, Guo Tian, Xiaoxiao Liu, Jie Wu, Cheng Ding, Danying Yan, Lanjuan Li & Shigui Yang. (2020) Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine 38:6, pages 1332-1344.
Crossref
Crossref
Chia‐Yin Chong, Chee‐Fu Yung, Cherie Gan, Szu‐Tien Thio, Natalie Woon‐Hui Tan, Nancy Wen‐Sim Tee, Cui Lin, Raymond Tze‐Pin Lin & Koh‐Cheng Thoon. (2019) The burden and clinical manifestation of hospitalized influenza among different pediatric age‐groups in the tropics. Influenza and Other Respiratory Viruses 14:1, pages 46-54.
Crossref
Crossref
Brandon Essink, Carlos Fierro, Jeffrey Rosen, Amparo L. Figueroa, Bin Zhang, Carole Verhoeven, Jonathan Edelman & Igor Smolenov. (2020) Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine 38:2, pages 242-250.
Crossref
Crossref
Clarisse M. Machado, Ana Carolina Mamana Fernandes de Souza, Camila Malta Romano, Wilton dos Santos Freire, Ângela Aparecida Costa, Walter Manso Figueiredo, Cláudio S. Pannuti & Expedito J.A. Luna. (2020) Influenza A and B in a cohort of outpatient children and adolescent with influenza like-illness during two consecutive influenza seasons. The Brazilian Journal of Infectious Diseases 24:1, pages 73-80.
Crossref
Crossref
Wonil Chae, Paul Kim, Hanna Kim, Yu Cheol Cheong, Young-Seok Kim, Sang Moo Kang & Baik L. Seong. (2019) Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies. Scientific Reports 9:1.
Crossref
Crossref
Guozhong He, Pengfei Yang, Qingli Yan & Chenglong Xiong. (2019) Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines. Antimicrobial Resistance & Infection Control 8:1.
Crossref
Crossref
Hsueh-Ju Chen, Chia-Ping Su, Ming-Tsan Liu & Tsung-Pei Tsou. (2019) Comparative epidemiology of influenza B by lineage in intensive care unit-admitted patients with complications: A nationwide study in Taiwan, 2013–2017. International Journal of Infectious Diseases 87, pages 67-74.
Crossref
Crossref
Cristina Carter, Katherine V. Houser, Galina V. Yamshchikov, Abbie R. Bellamy, Jeanine May, Mary E. Enama, Uzma Sarwar, Brenda Larkin, Robert T. Bailer, Richard Koup, Grace L. Chen, Shital M. Patel, Patricia Winokur, Robert Belshe, Cornelia L. Dekker, Barney S. Graham & Julie E. Ledgerwood. (2019) Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLOS ONE 14:9, pages e0222178.
Crossref
Crossref
Daniela Loconsole, Anna Lisa De Robertis, Anna Morea, Daniele Casulli, Rosanna Mallamaci, Simona Baldacci, Francesca Centrone, Viviana Bruno, Michele Quarto, Marisa Accogli & Maria Chironna. (2019) High Public-Health Impact in an Influenza-B-Mismatch Season in Southern Italy, 2017-2018. BioMed Research International 2019, pages 1-10.
Crossref
Crossref
Thomas Weigel, Remon Soliman, Michael W. Wolff & Udo Reichl. (2019) Hydrophobic-interaction chromatography for purification of influenza A and B virus. Journal of Chromatography B 1117, pages 103-117.
Crossref
Crossref
T. S. Saltykova, B. A. Zhigarlovsky, A. V. Ivanenko, N. A. Volkova, V. I. Antonova & N. I. Briko. (2019) Epidemiological characteristics of acute respiratory viral infection and influenza in Russian Federation and Moscow. Journal Infectology 11:2, pages 124-132.
Crossref
Crossref
A. A. Sominina, D. M. Danilenko, A. B. Komissarov, A. V. Fadeev, M. M. Pisareva, M. Yu. Eropkin, N. I. Konovalova, P. A. Petrova, A. A. Shtro, K. A. Stolyarov, L. S. Karpova, E. I. Burtseva & A. V. Vasin. (2018) SUMMARY OF INFLUENZA AND OTHER RESPIRATORY VIRUSES DETECTED AND CHARACTERIZED IN RUSSIA DURING 2017–2018 SEASON. Russian Journal of Infection and Immunity 8:4, pages 473-488.
Crossref
Crossref
Larisa Rudenko, Irina Kiseleva, Elena Krutikova, Ekaterina Stepanova, Andrey Rekstin, Svetlana Donina, Maria Pisareva, Elena Grigorieva, Kirill Kryshen, Arman Muzhikyan, Marina Makarova, Erin Grace Sparrow, Guido Torelli & Marie-Paule Kieny. (2018) Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. PLOS ONE 13:12, pages e0208028.
Crossref
Crossref
Anne Mosnier, Odile Launay, Luc Martinez, Gaëtan Gavazzi, Laurence Josset, Pascal Crepey, Claude Hannoun, Catherine Weil-Olivier & Jacques Gaillat. (2018) Vaccin grippal quadrivalent : quels changements pour quels bénéfices ?. La Presse Médicale 47:10, pages 842-853.
Crossref
Crossref
José Antonio López Trigo, Rosa López Mongil, Alberto Mariano Lázaro, Gloria Mato Chaín, Norberto Moreno Villajos & Primitivo Ramos Cordero. (2018) Vacunación frente a la gripe estacional en las personas mayores. Evaluación de la vacuna tetravalente. Informe de posicionamiento. Revista Española de Geriatría y Gerontología 53, pages 185-202.
Crossref
Crossref
Akinobu Hibino, Elie Massaad, Hiroki Kondo, Reiko Saito, Takashi Odagiri, Nobuhiro Takemae, Ryota Tsunekuni, Takehiko Saito, Yadanar Kyaw, Nay Lin, Yi Yi Myint, Htay Htay Tin, Nguyen Le Khanh Hang, Le Quynh Mai, Ren Yagami, Yugo Shobugawa, Tommy Lam & Hassan Zaraket. (2018) Neuraminidase inhibitor susceptibility and evolutionary analysis of human influenza B isolates from three Asian countries during 2012–2015. Infection, Genetics and Evolution 62, pages 27-33.
Crossref
Crossref
Peter Pushko, Irina Tretyakova, Rachmat Hidajat, Xiangjie Sun, Jessica A. Belser & Terrence M. Tumpey. (2018) Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone. Vaccine 36:29, pages 4346-4353.
Crossref
Crossref
Mira C. Patel, Kari Ann Shirey, Marina S. Boukhvalova, Stefanie N. Vogel & Jorge C. G. Blanco. (2018) Serum High-Mobility-Group Box 1 as a Biomarker and a Therapeutic Target during Respiratory Virus Infections. mBio 9:2.
Crossref
Crossref
Jin Lee, Kyung-Yil Lee, Jong-Hyun Kim, Chun Soo Kim, Byung Wook Eun, Hwang Min Kim, Dong Ho Kim, Young Jin Hong, Young Youn Choi, Dae Sun Jo, Sang Hyuk Ma & Jin Han Kang. (2018) Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study. Journal of Korean Medical Science 33:13.
Crossref
Crossref